Actively Recruiting
Phase III Open-Label Study of GQ1010 Antibody-Drug Conjugate for Adults With Advanced Solid Tumors
Led by GeneQuantum Healthcare (Suzhou) Co., Ltd. · Updated on 2025-02-10
260
Participants Needed
5
Research Sites
31 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GQ1010, a Trop-2 directed antibody-drug conjugate, in adults with advanced malignant solid tumors who have been previously treated. This open-label, multicenter Phase 12 study aims to assess the safety, tolerability, how the drug moves through the body, immune response, and early signs of anti-tumor effects in participants with various solid tumors that have relapsed or progressed after standard treatments or lack standard options. The study consists of three parts Phase 1a dose escalation to find safe and tolerable doses and the maximum tolerated dose, Phase 1b dose expansion to identify recommended doses for Phase 2, and Phase 2 to evaluate preliminary efficacy in five tumor type cohorts. GQ1010 is given intravenously every 14 or 21 days with dosing guided by a Bayesian Optimal Interval design. Multiple dose groups are included to evaluate safety and tolerability further in advanced tumor subjects. Participants will undergo screening and treatment for about one year, including evaluations of adverse events, dose limiting toxicities, tumor response using RECIST 1.1 criteria, pharmacokinetic measures, and immunogenicity. Safety and efficacy are monitored regularly through clinical assessments, tumor imaging, lab tests, and biomarker analyses. The study also tracks overall survival and disease progression over the treatment period.
CONDITIONS
Brief Title
A Study of GQ1010 in Subjects With Advanced Solid Tumors
Research Team
Y
Yan Shi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here